May 19th 2020: Special Encore "A New Parenteral Treatment for a Severe C. difficile Infection." |eCard

TROUBLE VIEWING? Click Here to view the Promo card on the web

SIGN-UP NOW! Click to become a Member for Free!

C. diff. Spores and More

Tuesday at 10 AM Pacific

May 19th 2020: Special Encore "A New Parenteral Treatment for a Severe C. difficile Infection."

Join us with our two guests: Dr Yannick Pletan, Independent Director Clinical development specialist,Doctor of medicine, and Georges Gaudriault, Scientific Director, PhD in molecular pharmacology. Both Dr. Pletan and Gaudriault will introduce and discuss DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics, announced the inclusion of the first patient in the Phase II trial testing DNV3837. DNV3837 targets the treatment of Clostridioides difficile (C. diff. ) infections

Read more

DOWNLOAD PDF

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel

LISTEN LIVE

EPISODE ON DEMAND

VIEW HOST PAGE

Questions? Comments?
Call In Live! Call-In
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guests

Yannick Pletan, MD Independent Director

Dr Yannick Pletan, Independent Director, Clinical development specialist at Deinove. Doctor of medicine (Paris Descartes University), pulmonologist and immunologist. He holds a Master’s degree in clinical pharmacology and pharmacokinetics, a diploma from the Advanced Leadership program (Harvard Business School) and one in Corporate Finance (HEC).

Read more

Georges Gaudriault, Ph.D. Scientific Director

Georges GAUDRIAULT, PhD, has nearly 20 years of experience in drug research and development. He then masters every step along the value chain, including regulatory aspects and market access. Before joining DEINOVE, he held for nine years the position of Chief scientific officer at MedinCell, a biopharmaceutical company specializing in long-acting drug delivery. He was also a Scientific director at ObeTherapy - a biotechnology start-up specializing in the discovery and development of therapies in the fields of obesity, hypercholesterolemia, and type II diabetes - and contributed to research at the Institut Curie. In addition, Georges GAUDRIAULT has solid experience in the United States, hav

Read more

Share This Episode

Share On Facebook

Share On Twitter

Share On LinkedIn

Connect with VoiceAmerica

Download our mobile apps